Patents Assigned to Inhibrx, Inc.
-
Patent number: 11976126Abstract: The disclosure relates generally to molecules that specifically engage death receptor 5 (DR5), a member of the TNF receptor superfamily (TNFRSF). More specifically the disclosure relates to multivalent and multispecific molecules that bind at least DR5.Type: GrantFiled: August 5, 2021Date of Patent: May 7, 2024Assignee: Inhibrx, Inc.Inventors: John C. Timmer, Kyle S. Jones, Amir S. Razai, Abrahim Hussain, Katelyn M. Willis, Quinn Deveraux, Brendan P. Eckelman
-
Patent number: 11965017Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a whey acidic protein (WAP) domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.Type: GrantFiled: October 8, 2020Date of Patent: April 23, 2024Assignee: InhibRx, Inc.Inventors: Brendan P. Eckelman, John C. Timmer, Peter L. Nguy, Grant B. Guenther, Quinn Deveraux
-
Patent number: 11945869Abstract: Provided herein are binding polypeptides that specifically bind PD-1. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific constructs and chimeric antigen receptors, that bind PD-1. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided PD-1 binding polypeptides for treating diseases and conditions, such as cancer.Type: GrantFiled: November 11, 2021Date of Patent: April 2, 2024Assignee: Inhibrx, Inc.Inventors: Rajay A. Pandit, John C. Timmer, Angelica N. Sanabria, Florian Sulzmaier, Brendan P. Eckelman
-
Publication number: 20240101704Abstract: The invention relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, results in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.Type: ApplicationFiled: November 27, 2023Publication date: March 28, 2024Applicant: Inhibrx, Inc.Inventors: Brendan P. ECKELMAN, Michael D. KAPLAN, Katelyn M. WILLIS, Quinn DEVERAUX, John C. TIMMER
-
Patent number: 11919963Abstract: Provided herein are VHH-containing polypeptides that bind CD123. Uses of the VHH-containing polypeptides are also provided.Type: GrantFiled: August 1, 2022Date of Patent: March 5, 2024Assignee: Inhibrx, Inc.Inventors: Chelsie Macedo, Kyle Jones, William Crago, Andrew Hollands, Milton Ma, John C. Timmer, Brendan P. Eckelman
-
Patent number: 11866507Abstract: The invention relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, results in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.Type: GrantFiled: April 11, 2018Date of Patent: January 9, 2024Assignee: Inhibrx, Inc.Inventors: Brendan P. Eckelman, Michael D. Kaplan, Katelyn M. Willis, Quinn Deveraux, John C. Timmer
-
Publication number: 20230416387Abstract: This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.Type: ApplicationFiled: December 16, 2022Publication date: December 28, 2023Applicant: Inhibrx, Inc.Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
-
Patent number: 11827691Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a (whey acidic protein) WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.Type: GrantFiled: June 22, 2020Date of Patent: November 28, 2023Assignee: InhibRx, Inc.Inventors: Brendan P. Eckelman, John C. Timmer, Peter L. Nguy, Grant B. Guenther, Quinn Deveraux
-
Publication number: 20230348600Abstract: Provided herein are binding polypeptides that specifically bind CD28. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific constructs that bind at least CD28. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors thereof, and methods of use and uses of the provided CD28 binding polypeptides for treating diseases and conditions, such as cancer.Type: ApplicationFiled: January 28, 2021Publication date: November 2, 2023Applicant: Inhibrx, Inc.Inventors: John C. TIMMER, Rutger H. JACKSON, Katelyn M. WILLIS, William S. CRAGO, Michael D. KAPLAN, Brendan P. ECKELMAN
-
Publication number: 20230331846Abstract: Provided herein are VHH-containing polypeptides that bind canine PD-1. In some embodiments, VHH-containing polypeptides that bind and antagonize canine PD-1 are provided. Uses of the VHH-containing polypeptides are also provided.Type: ApplicationFiled: May 3, 2021Publication date: October 19, 2023Applicant: Inhibrx, Inc.Inventors: Rajay Pandit, John C. Timmer, Brendan P. Eckelman, Quinn Deveraux
-
Publication number: 20230312716Abstract: Provided herein are VHH-containing polypeptides that bind CD33. Uses of the VHH-containing polypeptides are also provided.Type: ApplicationFiled: December 16, 2022Publication date: October 5, 2023Applicant: Inhibrx, Inc.Inventors: Kyle S. Jones, William Crago, Angelica Sanabria, Andrew Hollands, Jacob Gano, Milton Ma, John C. Timmer, Brendan P. Eckelman
-
Publication number: 20230295336Abstract: The invention relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, components of the multispecific polypeptides are connected by a non-cleavable linker. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.Type: ApplicationFiled: June 6, 2023Publication date: September 21, 2023Applicant: Inhibrx, Inc.Inventors: Brendan P. ECKELMAN, Michael D. KAPLAN, Katelyn M. WILLIS, John C. TIMMER
-
Publication number: 20230235005Abstract: Provided herein are polypeptide comprising a modified IL-2, wherein the modified IL-2 has reduced affinity for the IL-2 receptor relative to wild type IL-2. In some embodiments, polypeptides comprising a modified IL-2 that bind and agonize activated T cells are provided. Uses of the polypeptides comprising a modified IL-2 are also provided.Type: ApplicationFiled: July 1, 2021Publication date: July 27, 2023Applicant: Inhibrx, Inc.Inventors: John C. Timmer, Florian Sulzmaier, Katelyn M. Willis, Bryan R. Becklund, Brendan P. Eckelman
-
Publication number: 20230128188Abstract: Provided herein are VHH-containing polypeptides that bind OX40. In some embodiments, VHH-containing polypeptides that bind and agonize OX40 are provided. Uses of the VHH-containing polypeptides are also provided.Type: ApplicationFiled: August 8, 2022Publication date: April 27, 2023Applicant: Inhibrx, Inc.Inventors: John C. Timmer, William Crago, Kyle Jones, Katelyn Willis, Florian Sulzmaier, Bryan Becklund, Brendan P. Eckelman
-
Publication number: 20230065306Abstract: Provided herein are VHH-containing polypeptides that bind CD123. Uses of the VHH-containing polypeptides are also provided.Type: ApplicationFiled: August 1, 2022Publication date: March 2, 2023Applicant: Inhibrx, Inc.Inventors: Chelsie Macedo, Kyle Jones, William Crago, Andrew Hollands, Milton Ma, John C. Timmer, Brendan P. Eckelman
-
Patent number: 11566078Abstract: This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.Type: GrantFiled: October 15, 2019Date of Patent: January 31, 2023Assignee: Inhibrx, Inc.Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
-
Patent number: 11560428Abstract: Provided herein are VHH-containing polypeptides that bind CD33. Uses of the VHH-containing polypeptides are also provided.Type: GrantFiled: May 1, 2020Date of Patent: January 24, 2023Assignee: Inhibrx, Inc.Inventors: Kyle S. Jones, William Crago, Angelica Sanabria, Andrew Hollands, Jacob Gano, Milton Ma, John C. Timmer, Brendan P. Eckelman
-
Publication number: 20220323496Abstract: The present disclosure provides improved CLL-1 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.Type: ApplicationFiled: May 7, 2020Publication date: October 13, 2022Applicants: 2SEVENTY BIO, INC., INHIBRX, INC.Inventors: JORDAN JARJOUR, MARK POGSON, WAI-HANG LEUNG, LUCAS RASCON, ANGELICA SANABRIA, JOHN C. TIMMER, BRENDAN P. ECKELMAN
-
Publication number: 20220324942Abstract: The present disclosure provides improved CD33 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.Type: ApplicationFiled: May 7, 2020Publication date: October 13, 2022Applicants: 2SEVENTY BIO, INC., INHIBRX, INC.Inventors: JORDAN JARJOUR, MARK POGSON, WAI-HANG LEUNG, KYLE JONES, WILLIAM CRAGO, ANGELICA SANABRIA, ANDREW HOLLANDS, JACOB GANO, MILTON MA, JOHN C. TIMMER, BRENDAN P. ECKELMAN
-
Publication number: 20220315638Abstract: The present disclosure provides improved CD123 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.Type: ApplicationFiled: May 7, 2020Publication date: October 6, 2022Applicants: 2SEVENTY BIO, INC., INHIBRX, INC.Inventors: JORDAN JARJOUR, MARK POGSON, WAI-HANG LEUNG, CHELSIE MACEDO, KYLE JONES, WILLIAM CRAGO, ANDREW HOLLANDS, MILTON MA, JOHN C. TIMMER, BRENDAN P. ECKELMAN